View Older Stories View More Recent Stories

Apr 23, 2018 07:30AM Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID
Apr 23, 2018 07:30AM Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections
Apr 13, 2018 04:46PM Paratek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to Board
Apr 13, 2018 04:40PM Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors
Apr 12, 2018 07:30AM Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
Apr 11, 2018 08:30AM TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Apr 4, 2018 04:02PM Paratek's (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
Apr 4, 2018 04:01PM Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
Mar 30, 2018 08:00AM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 28, 2018 08:00AM Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Mar 16, 2018 08:00AM Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
Mar 2, 2018 08:00AM Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference
Mar 1, 2018 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2018 07:00AM Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019
Feb 27, 2018 04:05PM TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Feb 27, 2018 04:05PM Five Prime Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 5, 2018 07:34AM Paratek (PRTK) Completes Submission of NDA for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
Feb 5, 2018 07:30AM Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections
Feb 1, 2018 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 20, 2017 04:31PM Allergan (AGN) and Paratek (PRTK) Report FDA Accepted NDA For Seysara for Treatment of Moderate to Severe Acne
Dec 20, 2017 04:30PM FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne
Dec 1, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 7, 2017 04:05PM TESARO Announces Third-Quarter 2017 Operating Results
Nov 1, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 29, 2017 09:00PM Oracle Health Sciences Collaborates with dMed in China to Enhance Pharmacovigilance Management with Oracle Health Sciences Argus Safety
Oct 2, 2017 04:01PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 29, 2017 01:39PM Citi Appointed Depositary Bank for Zai Lab Limited’s Sponsored ADR Program
Sep 20, 2017 12:49PM Zai Lab Ltd. (Nasdaq: ZLAB) to Ring The Nasdaq Stock Market Opening Bell in Celebration of their IPO
Zai Lab Launches Hong Kong Secondary Listing
View More Recent Stories View Older Stories